한글목차

근위축성측색경화증(ALS) 치료 시장 규모는 2025년 8억 136만 달러에서 2034년에는 12억 6,033만 달러에 달할 것으로 예측되며, 2026년부터 2034년까지 CAGR 5.16%로 성장할 전망입니다.

근위축성측색경화증(ALS) 치료 시장은 이 신경퇴행성 질환의 유병률 증가와 치료 옵션의 발전에 힘입어 괄목할 만한 성장을 보이고 있습니다. 운동신경세포의 진행성 퇴행이 특징인 ALS는 복잡한 병태생리로 인해 치료에 있어 특별한 어려움을 겪고 있습니다. 그러나 최근 릴루졸, 에달라본과 같은 질병 변형 치료제의 개발 동향은 질병 진행 지연과 환자 예후 개선에 대한 유망한 결과를 보여주고 있습니다. 유전자 치료와 줄기세포 치료를 포함한 새로운 치료 접근법에 대한 지속적인 연구는 ALS 관리의 전망을 더욱 넓혀가고 있습니다.

또한, ALS에 대한 인식의 증가와 전문 연구 프로젝트의 확립은 효과적인 치료법에 대한 수요를 촉진하고 있습니다. 지원 단체와 조직은 ALS에 대한 인식 제고와 연구 자금 조달에 중요한 역할을 하고 있으며, 이는 ALS 치료에 대한 투자 증가로 이어지고 있습니다. 또한, 맞춤형 의료에 대한 관심이 ALS 치료 시장에 영향을 미치고 있으며, 임상의들은 환자 개개인의 프로필과 유전적 요인에 따른 중재법 적용을 모색하고 있습니다. 이 접근법은 치료 효과를 높이고 환자 개개인의 고유한 니즈에 대응하는 것을 목표로 합니다.

또한, 다직종 협력 치료 모델의 통합은 ALS 관리를 변화시키고 있습니다. 신경과 전문의, 물리치료사, 작업치료사, 영양사가 협력하는 접근법은 ALS 환자가 직면한 다양한 문제에 대응하는 종합적인 치료 제공에 필수적입니다. 이 종합적인 접근법은 삶의 질을 향상시킬 뿐만 아니라, 질병 경과를 통해 환자와 가족을 지원합니다. 결론적으로, ALS 치료 시장은 혁신, 인식 개선, 그리고 이 어려운 치료 분야에서 환자 치료 개선을 위한 노력으로 인해 견고한 성장이 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 근위축성측색경화증 치료 시장 : 약물별

제5장 세계의 근위축성측색경화증 치료 시장 : 유형별

제6장 세계의 근위축성측색경화증 치료 시장 : 유통 채널별

제7장 세계의 근위축성측색경화증 치료 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

영문목차

The Amyotrophic Lateral Sclerosis Treatment Market size is expected to reach USD 1260.33 Million in 2034 from USD 801.36 Million (2025) growing at a CAGR of 5.16% during 2026-2034.

The amyotrophic lateral sclerosis (ALS) treatment market is witnessing significant growth, driven by the increasing prevalence of this neurodegenerative disease and advancements in therapeutic options. ALS, characterized by the progressive degeneration of motor neurons, presents unique challenges in treatment due to its complex pathophysiology. However, recent developments in disease-modifying therapies, such as riluzole and edaravone, have shown promise in slowing disease progression and improving patient outcomes. Ongoing research into novel therapeutic approaches, including gene therapy and stem cell treatments, is further expanding the landscape of ALS management.

Moreover, the growing awareness of ALS and the establishment of dedicated research initiatives are propelling the demand for effective treatment options. Advocacy groups and organizations are playing a crucial role in raising awareness and funding research, leading to increased investment in ALS therapies. Additionally, the focus on personalized medicine is influencing the ALS treatment market, as clinicians seek to tailor interventions based on individual patient profiles and genetic factors. This approach aims to enhance treatment efficacy and address the unique needs of each patient.

Furthermore, the integration of multidisciplinary care models is transforming the management of ALS. Collaborative approaches involving neurologists, physical therapists, occupational therapists, and nutritionists are essential for providing comprehensive care that addresses the diverse challenges faced by ALS patients. This holistic approach not only improves quality of life but also supports patients and their families throughout the disease journey. In conclusion, the ALS treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient care in this challenging therapeutic area.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drugs

• Riluzole
• Edaravone
• Others

By Type

• Sporadic ALS
• Familial ALS

By Distribution Channel

• Hospital Pharmacies
• Online Providers
• Drug Stores and Retail Pharmacies

COMPANIES PROFILED

• Alkem Laboratories Ltd, Aquestive Therapeutics Inc, Italfarmaco SPA, Viatris Inc, Mitsubishi Chemical Group Corporation, Amylyx Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd, Glenmark Pharmaceuticals Limited, Covis Pharma GmbH, Sun Pharmaceutical Industries Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY DRUGS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drugs
• 4.2. Riluzole Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Edaravone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Sporadic ALS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Familial ALS Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Online Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Drug Stores and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drugs
  • 7.2.2 By Type
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drugs
  • 7.3.2 By Type
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drugs
  • 7.4.2 By Type
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drugs
  • 7.5.2 By Type
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drugs
  • 7.6.2 By Type
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Alkem Laboratories Ltd
  • 9.2.2 Aquestive Therapeutics Inc
  • 9.2.3 Italfarmaco S.P.A
  • 9.2.4 Viatris Inc
  • 9.2.5 Mitsubishi Chemical Group Corporation
  • 9.2.6 Amylyx Pharmaceuticals Inc
  • 9.2.7 Otsuka Pharmaceutical Co. Ltd
  • 9.2.8 Glenmark Pharmaceuticals Limited
  • 9.2.9 Covis Pharma GmbH
  • 9.2.10 Sun Pharmaceutical Industries Ltd